The changing face of Australian data reforms: Impact on pharmacoepidemiology research

Main Article Content

Juliana de Oliveira Costa
Claudia Bruno
Andrea L Schaffer
Smriti Raichand
Emily A Karanges
Sallie-Anne Pearson


A wealth of data is generated through Australia’s universal health care arrangements. However, use of these data has been hampered by different federal and state legislation, privacy concerns and challenges in linking data across jurisdictions. A series of data reforms have been touted to increase population health research capacity in Australia, including pharmacoepidemiology research. Here we catalogued research leveraging Australia’s Pharmaceutical Benefits Scheme (PBS) data (2014–2018) and discussed these outputs in the context of previously implemented and new data reforms.

We conducted a systematic review of population-based studies using PBS dispensing claims. Independent reviewers screened abstracts of 4,996 articles and 310 full-text manuscripts. We characterised publications according to study population, analytical approach, data sources used, aims and medicines focus.

We identified 180 studies; 133 used individual-level data, 70 linked PBS dispensing claims with other health data (66 across jurisdictions). Studies using individual-level data focussed on Australians receiving government benefits (87 studies) rather than all PBS-eligible persons. 63 studies examined clinician or patient practices and 33 examined exposure-outcome relationships (27 evaluated medicines safety, 6 evaluated effectiveness). Medicines acting on the nervous and cardiovascular system account for the greatest volume of PBS medicines dispensed and were the most commonly studied (67 and 40 studies, respectively). Antineoplastic and immunomodulating agents account for approximately one third of PBS expenditure but represented only 10% of studies in this review.

The studies in this review represent more than a third of all population-based pharmacoepidemiology research published in the last three decades in Australia. Recent data reforms have contributed to this escalating output. However, studies are concentrated among specific subpopulations and medicines classes, and there remains a limited understanding of population benefits and harms derived from medicines use. The current draft Data Availability and Transparency legislation should further bolster efforts in population health research.


  • Australia has the potential to undertake whole-of-health care and whole-of-population research using data from its universal health care system.
  • Reforms related to data availability and use in Australia have facilitated linkage of Australian Government and state health data, such as the Pharmaceutical Benefits Scheme (PBS) dispensing claims, hospitalisations, and deaths.
  • Encouragingly, in the past 5 years research output in population-based pharmacoepidemiology research increased substantially. The studies catalogued in this review represent more than a third of all population-based pharmacoepidemiology studies published in the last 30 years in Australia.
  • The majority of studies published in recent years used individual-level data (n = 133), 70 linked PBS dispensing claims with other health data (66 across jurisdictions). Evidence derived from these studies is concentrated among subpopulations and on medicines acting on the nervous system and cardiovascular system.
  • There is still very limited evidence on the real-world safety and effectiveness of medicines in Australia.
  • New legislative reform, particularly the Data Availability and Transparency Act will be formalised in the near future and will accelerate population-based research efforts in Australia, including pharmacoepidemiology.


Worldwide population-based health administrative data are being mobilised to evaluate the quality and outcomes of care. The data collected through Australia’s universal health care arrangements have the potential to advance knowledge in population health and generate timely, comprehensive clinical and policy insights. However, population-based research has been hampered by the heterogeneity in legislation, regulations and guidelines at national and state levels plus privacy concerns and the ability to link person-level data across jurisdictional boundaries [1].

The Western Australia Data Linkage System pioneered cross-jurisdictional data linkage in the late 90s, supporting a broad range of population-based research [26]. However, it wasn’t until the mid-2000s that key initiatives enhanced the entire country’s capability to leverage population-based health data for research. These include the establishment of: Australian Government approved Integrating Authorities that probabilistically link person-level data across jurisdictional boundaries (using best-practice privacy preserving protocols); and data safe havens where sensitive data can be accessed and analysed by approved researchers [7]. More recently, the 2017 Australian Productivity Commission’s Data Availability and Use inquiry recommended sweeping reform to drive efficiency, safety and support decision-making [1]. The Federal government’s response to the Inquiry [8] led to the establishment of the Office of the National Data Commissioner (ONDC) and the development of a legislative package to streamline the sharing of government data for service provision, policy evaluation and research, while preserving strict data privacy and confidentiality provisions. Together, these initiatives are expected to bolster Australian population health research, including the field of pharmacoepidemiology, the foundation of medicines policy research.

In Australia, it is estimated that more than 27 million individual Pharmaceutical Benefits Scheme (PBS) prescriptions are in use on any given day; more than nine million people are taking at least one prescribed medicine daily and two million are taking five or more daily [9]. PBS data linked to other administrative claims are a powerful tool to examine real-world medicines use, safety, effectiveness, and value for money in populations not typically represented in clinical trials [10, 11]. Importantly, to assess these outcomes, PBS data, under the custodianship of the Australian Government, needs to be linked at the individual-level with outcomes data such as hospitalisations, which are under the custodianship of the States and Territories. This situation has led researchers in this field to rely on publicly available aggregated data and/or stand-alone, bespoke data collections with individual-level data as the primary sources for evidence generation [1].

Our previous systematic review of population-based research leveraging PBS data over a 25 year period to 2013, documented relatively few published studies, especially compared to the pharmacoepidemiology output in the Nordic countries over a period of six years (228 versus 515 studies) [12]. We also demonstrated that output had increased substantially from 2007 to 2013, pointing to the benefits of infrastructure development in the mid-2000s and the use of Department of Veterans Affair’s data collections (DVA). As a single payer, the DVA has data on a broad range of health services used by their clients that can be leveraged for quality use of medicines and outcomes research. However, we also highlighted significant blind spots in our understanding of medicine use and outcomes in Australia. In particular, we reported a paucity of published literature examining specific population sub-groups (including children and pregnant women), specific medicines (including high-cost therapies prescribed by specialists) and studies linking individual-level medicines exposure and outcomes to quantify benefits and harms [13]. Here we catalogue contemporary population-based medicines policy research leveraging Australia’s PBS and other data in the period 2014–2018 and discuss these outputs in the context of Australia’s data reforms.


Setting and data of interest

Australia has a universal health care system providing access to subsidised prescription medicines to citizens and eligible residents and clients of the DVA via the PBS and the Repatriation Pharmaceutical Benefits Scheme (RPBS), respectively. People contribute a co-payment towards the cost of their medicines, which varies depending on their entitlements. Our review focusses on studies using routinely collected data on medicines dispensed through PBS and RPBS. These dispensing claims are processed by Services Australia (previously the Department of Human Services and Medicare Australia) and are provided to the Australian Government Department of Health and the DVA for monitoring, evaluation, and health service planning. These data are available to third parties, publicly or by request, for monitoring, evaluation, and research (see Supplementary Table 1).

Study identification

We searched Medline and Embase from January 2013 through December 2018 using a combination of keywords and search terms describing medicines use (e.g. prescription drugs, drug therapy, drug utilisation) with PBS dispensing data sources (see Supplementary Appendix A for search strategy). We also conducted searches on key researchers in the field of medicines policy research in Australia and screened the reference lists of all included studies (Figure 1).

Figure 1: Identification of studies included in the systematic review.

Study eligibility criteria

We included full-text English-language studies using PBS and/or RPBS dispensing claims data to measure patterns of medicines use or using medicines as a proxy of a health condition or an outcome. We excluded studies: focussing exclusively on medicine expenditure or modelling; using dispensing data obtained directly from pharmacies; requiring individual informed consent to access dispensing data; or using data derived from state-based registries.

Study selection and data extraction

Two reviewers (CB, SP) screened a random 20% sample of titles and abstracts independently to identify potentially relevant studies for inclusion; one reviewer (CB) screened the remainder. Two reviewers (JOC, CB) extracted data independently from all included studies and disagreements were resolved by discussion. We extracted the following key features of each study (Box 1):

Study characteristics Publication year, journal, study aims, funding source, and setting
Study period Difference between the earliest and latest month and year of observation
Publication lag The earliest month and year of publication minus last month and year of study observation
Age profile of study population No age restrictions (entire eligible population), elderly (≥65 years), adults (≥ 18 years), women of childbearing age, or children
Beneficiary status of study population All PBS beneficiaries, people receiving government benefits and eligible to pay lower PBS co-payments (concessional beneficiaries) or clients of the DVA
Analytical approach Individual-level studies (track patients and/or providers over time) or claims-level studies. Studies using both approaches were classified as ‘individual-level’
Data source(s) Primary dispensing claims dataset (e.g. PBS 10% sample, RPBS data), geographic coverage (e.g. national or state level), the inclusion of other dispensing claims or data sources and individual-level linkage to other data sources.
Box 1: Features extracted from included studies.

Classification of studies

We classified the broad study focus into six themes; (1) Medicine utilisation: examined trends and patterns of dispensing overall or stratified by gender, age, and medicine or additional variables; (2) Clinician practices: used individual-level data to study prescribing patterns (e.g. concomitant or inappropriate prescribing); (3) Patient practices: used individual-level data to examine patient behaviour around medicines use, such as medicine persistence or adherence; (4) Exposure and outcomes: 4A) investigated the relationship between medicine use and at least one outcome, such as death or hospital admission (‘medicine use and outcomes’), OR 4B) investigated the relationship between other exposures (e.g. device use) and at least one outcome but used dispensing claims to define a cohort, comorbidities or an outcome (‘other exposure and outcomes’); (5) Intervention impacts: examined the effect of one or more population-level interventions on prescribing or another outcome, classified as educational (e.g. prescriber feedback and education), policy (e.g. subsidy changes and restrictions), media (e.g. advertising campaigns), or multi-faceted (combination of the above); (6) Methods: used dispensing data to develop and refine pharmacoepidemiological techniques (e.g. validation of prescribing indicators) or study protocols reporting data based on dispensing claims.

Medicines focus of studies

We assigned WHO Anatomical Therapeutic Chemical (ATC) classifications to the medicine focus of each study [14]. We also report the proportion of studies according to their medicine focus relative to the proportion of PBS volume and spend for these classes by ATC code.


Due to the heterogeneity of study methodology, we did not assess individual study quality. However, we extracted 23 items pertaining to the REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) checklist [15] to describe areas of underreporting. Two reviewers (JOC, CB) independently reviewed all articles published in the most recent year (2018); disagreements in extraction were resolved by discussion. For each item (see Supplementary Appendix B) we allocated a score of 1 if studies reported the item. As some items were not applicable for some studies, we calculated the RECORD score as the percentage of items meeting the criteria in relation to the overall applicable items for each study.

We report the results of this review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [16].


We identified 4,996 studies through electronic searches and 14 through manual searches. After excluding duplicate records, we screened titles and abstracts of 4,362 articles and assessed 310 full-text manuscripts for eligibility. This review included 180 eligible studies (Figure 1) (see Supplementary Appendix C for the bibliography of included studies and Supplementary Appendix D for details of study features).

Study characteristics (Table 1 and Supplementary Figure 1)

Characteristic All studies, n (%) N = 180 Claims-level studies, n (%) n = 47 Individual-level studies, n (%) n = 133
Publication Year
2014# 20 (11.1) 4 (8.5) 16 (12.1)
2015 33 (18.3) 10 (21.3) 23 (17.3)
2016 35 (19.4) 11 (23.4) 24 (18.0)
2017 37 (20.6) 9 (19.1) 28 (21.1)
2018 55 (30.6) 13 (27.7) 42 (31.6)
Publication lag (time between last observation year and publication year)
<1 year 18 (10.0) 5 (10.6) 13 (9.8)
1–2 years 86 (47.8) 28 (59.6) 58 (43.6)
3–5 years 47 (26.1) 10 (21.3) 37 (27.8)
>5 years 29 (16.1) 4 (8.5) 25 (18.8)
Median publication lag, months (IQR) 32.5 (22.0; 49.0) 29.0 (19.0; 40.0) 34.0 (23.0; 50.0)
Study Population: Age profile
No age restrictions 91 (50.6) 44 (93.6) 47 (35.3)
Elderly (≥ 65 years) 55 (30.6) 0 (0.0) 55 (41.4)
Adults (≥ 18 years) 26 (14.4) 1 (2.1) 25 (18.8)
Women of childbearing age 6 (3.3) 2 (4.3) 4 (3.0)
Children 2 (1.1) 0 (0.0) 2 (1.5)
Study population: Beneficiary status
All PBS beneficiaries 89 (49.5) 43 (91.5) 46 (34.6)
Concessional PBS beneficiaries† 35 (19.4) 4 (8.5) 31 (23.3)
Clients of the DVA 56 (31.1) 0 (0.0) 56 (42.1)
Data sources
Dispensing claims only 62 (34.4) 18 (38.3) 44 (33.1)
Dispensing claims & other health data 118 (65.6) 29 (61.7) 89 (66.9)
Primary dispensing claims data
Publicly available 30 (16.7) 29 (61.7) 1 (0.8)
Medicare Statistics Online 18 (10.0) 18 (38.3) 0 (0.0)
Australian Statistics on Medicines 9 (5.0) 9 (19.1) 0 (0.0)
Section 85 extract 2 (1.1) 2 (4.3) 0 (0.0)
10% MBS-PBS sample 1 (0.6) 0 (0.0) 1 (0.8)
Available by request 141 (78.3) 14 (29.8) 127 (95.5)
PBS ad hoc extracts 38 (21.1) 8 (17.0) 30 (21.8)
RPBS 56 (31.1) 0 (0.0) 56 (42.1)
PBS 10% sample 39 (21.7) 1 (2.1) 38 (28.6)
DUSC 8 (4.4) 5 (10.6) 3 (2.3)
Not specified 9 (5.0) 4 (8.5) 5 (3.7)
Geographic coverage of primary dispensing data*
National 153 (85.0) 41 (87.2) 111 (83.5)
Western Australia 12 (6.7) 0 (0.0) 12 (9.0)
New South Wales 14 (7.8) 2 (4.3) 12 (9.0)
Other states/territories 5 (2.8) 5 (10.6) 0 (0.0)
Study focus
Medicine utilisation 36 (20.0) 36 (76.6) 0 (0.0)
Clinician practices 47 (26.1) 0 (0.0) 47 (35.3)
Patient practices 16 (8.9) 0 (0.0) 16 (12.0)
Intervention impacts 18 (10.0) 5 (10.6) 13 (9.8)
Exposure and outcomes 38 (21.1) 5 (10.6) 33 (24.8)
Medicine use and outcomes 33 (18.3) 4 (8.5) 29 (21.8)
Other exposures and outcomes 5 (2.8) 1 (2.1) 4 (3.0)
Methods 25 (13.9) 1 (2.1) 24 (18.0)
No funding 23 (12.8) 17 (36.2) 6 (4.5)
Not reported 18 (10.0) 11 (23.4) 7 (5.2)
One or more
Government 122 (67.8) 12 (25.5) 110 (82.7)
University 22 (12.2) 4 (8.5) 18 (13.5)
Industry 14 (7.8) 1 (2.1) 13 (9.8)
Other 25 (13.9) 8 (17.0) 17 (12.8)
Table 1: Study characteristics.

We observed a steady increase in the number of studies published annually and a sharp rise in 2018; this last observation year accounting for nearly one-third of all studies published in the period. Most studies used individual-level data (133 studies, 74%). The time between the study observation end date and publication was up to 2-years for 58% of studies; 16% of studies had a publication lag of more than 5 years. The median lag time for claims-level studies was 29 months and for individual-level studies, 34 months.

Age profile and beneficiary status of the study population (Table 1)

Approximately half of the 180 studies did not place age restrictions on their study cohorts (91 studies, 51%). The remaining studies restricted cohorts to people aged 65 years or older (55 studies, 31%) or people aged 18 years or older (26 studies, 14%). Five studies focussed on women of childbearing age and two on children. Approximately half of the studies restricted their populations to concessional beneficiaries or DVA clients (91 studies, 51%). Approximately 90% of studies using claims-level analyses used the entire PBS-eligible population. In contrast, approximately 65% of studies using individual-level analyses restricted their cohorts to the elderly, DVA clients or concessional beneficiaries.

Data sources (Table 1, Figure 2)

Figure 2: Number of publications (cumulative) according to primary dispensing claims data.

Approximately two-thirds of studies leveraged dispensing claims and other health data (118 studies, 66%). Approximately 20% of studies used publicly available dispensing claims and 78% used data available by request, with a marked increase in the use of the PBS 10% sample and PBS ad hoc extracts over time.

Two-thirds of claims-level studies used publicly available data; 62% of these also included other unlinked health data. Individual-level studies used RPBS data (42%), the PBS 10% sample (29%) or ad hoc data extracts (22%). These individual-level studies were Australian-wide or restricted to residents of Western Australia and/or New South Wales. Seventy of these studies linked individual-level dispensing claims to other health data such as hospitalisation data, medical services claims, residential aged care claims, emergency department data, or cancer and perinatal registries; 66 were linked across jurisdictions (data not shown in table).

Study focus (Table 1 and Figure 3)

Figure 3: Number of studies according to study focus and analytical approach.

Approximately one-third of all studies used individual-level data to examine clinician or patient practices (47 and 16 studies, respectively). Individual and claims-level exposure-outcomes studies accounted for 21% of all studies, 27 of the 38 studies evaluated medicine safety and 6 evaluated medicine effectiveness. One-fifth of all studies used claim-level data to investigate medicine utilisation (36 studies); methodological studies and those evaluating intervention impacts each accounted for around 24% of all studies (25 and 18 studies, respectively).

Medicines focus (Table 2)

Anatomical therapeutic classification first level grouping Claims-level studies n Individual-level studies n All studies n % PBS volume 2018# % PBS cost 2018# %
A Alimentary tract and metabolism 7 17 24 13.6 15.5 8.6
B Blood and blood forming organs - 17 17 9.7 4.6 5.6
C Cardiovascular system 6 34 40 22.7 31.5 8.4
G Genito-urinary system and sex hormones 3 9 12 6.8 1.9 2.0
H Systemic hormonal preparations 1 4 5 2.8 1.8 1.4
J Anti-infectives for systemic use 5 6 11 6.3 6.3 16.4
L Antineoplastic & immunomodulating agents 1 14 17 9.7 1.9 32.0
M Musculoskeletal system 1 14 15 8.5 3.4 2.9
N Nervous system 20 47 67 38.1 22.1 11.2
R Respiratory system 6 8 14 8.0 5.9 4.8
Other ATC groups** 0 6 6 3.4 5.2 6.7
All ATC groupings 1 21 22 12.5 - -
Table 2: Number and proportion of studies by pharmacological group compared to PBS volume and PBS expenditure (2014–2018). Study could be classified under more than one pharmacological group (N = 176*).

The most commonly studied medicines were those acting on the nervous system (38%) and cardiovascular system (23%), followed by those acting on the alimentary tract and metabolism (14%). In general, the most commonly studied medicines groups were also the medicines groups accounting for the greatest proportion of PBS dispensing in 2018. However, this medicine focus does not align with the proportion of PBS expenditure. For example, PBS expenditure with antineoplastic and immunomodulating agents represented 32% of the PBS spend in 2018 but less than 10% of the studies published in this review.

Reporting of the included studies – RECORD (Supplementary Figure 2)

Of the 55 studies published in 2018, we excluded seven methodological studies for which most of the RECORD items would not be applicable. From the 48 studies evaluated, the median RECORD score was 95% (interquartile range 90–100%); 13 (27%) studies scored 100%. The most underreported items were: study design, either by not reporting this item in the abstract (14 studies, 30%) or in the methods (9 studies, 19%), followed by the type of data used (14 studies, 30%), and methods of population selection (8 studies, 17%). Moreover, two-thirds of studies using linked data did not report the use of linked data in the abstract.


The exponential growth and availability of health data has created new opportunities to generate high-quality real-world evidence in many jurisdictions across the globe, contributing to the growth in pharmacoepidemiology research. We observed a marked increase in Australian output in this field; studies identified in this 5-year systematic review represented more than one-third of all population-based pharmacoepidemiology publications in the last three decades in Australia (Supplementary Figure 3). [13] In the current review period, we also observed an increase in the use of individual-level data and studies linking dispensing claims with other data collections. These studies represented more than half of individual-level and data linkage studies in pharmacoepidemiology in the last 30 years in Australia.

There is little doubt that several initiatives, including significant investment in data linkage infrastructure in Australia, have been pivotal in the growth in data availability and pharmacoepidemiology research. Here, we highlight those initiatives specific to the PBS data collection addressing the creation and accessibility of datasets, and challenges related to data ascertainment and interpretation. We further discuss the pharmacoepidemiology outputs in the context of Australia’s data current and future reforms.

Initiatives improving availability and ascertainment of dispensing claims data

First, the availability of a standardised data collection of person-level dispensing claims for a 10% sample of PBS-eligible people (“PBS 10%”) has contributed to the rapid increase in the number of studies using individual-level dispensing claims over time. The PBS 10% sample dataset, established in 2005, contains the entire PBS-claims history for a 10% random selection of PBS-eligible Australians. To minimise the risk of re-identification, the data is limited to a population sample, offset dates of dispensing by up to 14 days (but identically for each person), and it is not permitted to be linked to any other dataset. The collection is provided to approved third parties on a fee-for-service basis, has a streamlined governance process and approved organisations can hold longitudinal data that is updated at least quarterly. The earliest research studies using this collection were published between 2008–2013 [1722]. In the period of the current review, 39 studies have been published using this collection. The governance arrangements allow relatively rapid turnaround for approval of studies using contemporary data. This is a model that should be replicated across other data collections, including those with PBS dispensing claims linked to other health datasets.

Second, individual-level studies using PBS data prior to 2012 were often restricted to people receiving government entitlements to ensure complete capture of dispensing records [23]. The 2012 reform allowing the capture of all PBS dispensings (irrespective of whether they attracted a government subsidy) led to an increase in individual-level studies conducted across the entire eligible Australian population, not just in people receiving government benefits [13]. However, the collection does not contain information on private prescriptions, has limited capture of highly specialised medicines dispensed in public hospitals prior to 2013 and no information on prescription indication, prescribed daily dosage, and treatment duration. These limitations are not uncommon in community-based dispensing claims data, but it is important to consider these in pharmacoepidemiological study designs [23, 24].

With respect to undertaking exposure-outcomes studies, the Australian Institute of Health and Welfare’s development of multi-source enduring linked data assets (MELDAs) comprising continuing cross-jurisdictional, person-level linkages of medicines exposure with hospitalisation and mortality data show strong potential to further accelerate national population-based research capacity [25, 26]. At the time of writing, there were no formal policies around third-party access (including to academic researchers) to the current suite of MELDAs; this should be considered an immediate priority to realise this significant investment in public money [27].

Future directions

In July 2019, quality use of medicines and medicines safety was announced as Australia’s tenth national health priority [28, 29]. Studies catalogued in this systematic review provide contemporary evidence assessing quality use of medicines including the impact of medicines policy interventions, [3032] medicine use in populations not always represented in clinical trials, [33, 34] and adherence with current treatment guidelines [3537]. However, there is a need for greater focus on outcomes studies, especially pertaining to medicine safety, and with greater attention to vulnerable population sub-groups [38].

Despite advances, studies examining clinician and patient practices, as well as medicines utilisation studies, still represented a large proportion of the body of literature (Supplementary Figure 3) [13]. Further, the evidence base is still dominated by studies on cardiovascular medicines and those acting on the nervous system and in elderly Australians. Significant blind spots remain in our understanding of real-world medicine effectiveness and safety, particularly in Australians who do not receive government benefits and in populations consistently excluded from clinical trials, such as women of childbearing age and children. In this context, individual-level dispensing claims linked to health outcomes data, would provide a deeper understanding of the benefits and harms derived from medicine use, including indications for prescribing, clinical diagnoses, and other patient risk factors.

Historically, researchers have faced trade-offs between the ease of using readily available individual-level data, such as stand-alone PBS dispensing claims with limited clinical information (comprising the majority of individual-level studies in our review) or investing in the long process of gaining approvals and access to linked data [39, 40]. Encouragingly, we observed an increasing number of studies based on dispensing claims linked at the individual level to other data sources and we anticipate a further upswing in these types of studies in light of the major reforms underway in Australia. Particularly the new Data Availability and Transparency legislation, designed to maximise the value of Australian Government public sector data for service delivery and research. The legislation creates roles and responsibilities to data sharing. It adopts a guidance package to allow consistent practices across jurisdictions and safe sharing of data for public good purposes, including research and development, overriding secrecy provisions [41].

Other Commonwealth countries with similar health care systems and political structures, such as Canada and the United Kingdom, have bolstered their research capability by establishing independent centres serving the specific needs of the research community and closing the gap between linkage and analysis [42, 43]. Australia would benefit from adopting a similar model to harness data from its health care system covering over 25 million citizens and residents.

Limitations of this review

Our systematic review is not without limitations. We have focussed on studies using only routinely collected data and did not include studies using PBS data that required specific individual consent. We developed an arbitrary classification to classify studies by their main focus and given the high degree of variability both within and across studies, many could have been classified under alternative categories. Finally, we only addressed the reporting quality of studies published in 2018, identifying key elements that future studies should consider increasing their transparency and reproducibility and did not assess the methodological quality or relevance of included studies.


Here we used pharmacoepidemiology research as an exemplar to demonstrate the way in which data reforms have supported population health research in Australia. While our findings are encouraging in that we have observed significant growth in output in a five-year period, there is still some way to go before we realise the full potential of Australia’s administrative data in population-based research. Major legislative reform currently in place is likely to further break down barriers to facilitate more timely and comprehensive research to support clinical and policy decision-making.

Supplementary Files


This research is supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence (ID: 1196900). A.L.S. is supported by an NHMRC Early Career Fellowship (ID: 1158763).


  1. Productivity Commission 2017. Data availability and use, Report No. 82,. Canberra. Available at:

  2. Kelman CW, Bass AJ, Holman CD. Research use of linked health data–a best practice protocol. Aust N Z J Public Health. 2002;26(3):251–5. 10.1111/j.1467-842x.2002.tb00682.x
  3. Price SD, Holman CD, Sanfilippo FM, Emery JD. Are older Western Australians exposed to potentially inappropriate medications according to the Beers Criteria? A 13-year prevalence study. Australas J Ageing. 2014;33(3):E39–48. 10.1111/ajag.12136
  4. Gunnell AS, Hung J, Knuiman MW, Nedkoff L, Gillies M, Geelhoed E, et al. Secondary preventive medication use in a prevalent population-based cohort of acute coronary syndrome survivors. Cardiovascular Therapeutics. 2016;34(6):423–30. 10.1111/1755-5922.12212
  5. Colvin L, Gill AW, Slack-Smith L, Stanley FJ, Bower C. Off-Label Use of Ondansetron in Pregnancy in Western Australia. Biomed Research International. 2013;909860. 10.1155/2013/909860
  6. Price SD, Holman CDAJ, Sanfilippo FM, Emery JD. Use of case–time–control design in pharmacovigilance applications: exploration with high-risk medications and unplanned hospital admissions in the Western Australian elderly. Pharmacoepidemiology and Drug Safety 2013;22:1159–70. 10.1002/pds.3469
  7. Flack F, Smith M. The Population Health Research Network - Population Data Centre Profile. Int J Popul Data Sci. 2019;4(2):1130. 10.23889/ijpds.v4i2.1130
  8. Department of the Prime Minister Cabinet, 2018. The Australian Government’s Response to the Productivity Commission Data Availability and Use Inquiry. Available at:

  9. Wylie C DB, Brett J, Pearson SA, Buckley NA. A national study on prescribed medicine in Australia on a typical day. Pharmacoepidemiology & Drug Safety. 2020; 29(9):1046–1053. 10.1002/pds.5093
  10. World Health Organization. (1988). Guidelines for developing national drug policies. World Health Organization.

  11. Geneva, Switzerland: WHO Press, World Health Organization; 2011.
  12. Wettermark B, Zoëga H, Furu K, Korhonen M, Hallas J, Nørgaard M, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research–a literature review. Pharmacoepidemiol Drug Saf. 2013;22(7):691–9. 10.1002/pds.3457
  13. Pearson SA, Pesa N, Langton JM, Drew A, Faedo M, Robertson J. Studies using Australia’s Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: a systematic review of the published literature (1987–2013). Pharmacoepidemiol Drug Saf. 2015;24(5):447–55. 10.1002/pds.3756
  14. Norway: Structure and principles Oslo; 2011.
  15. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. 10.1371/journal.pmed.1001885
  16. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. 10.1371/journal.pmed.1000097
  17. Simons LA, Ortiz M, Calcino G. Long term persistence with statin therapy Experience in Australia 2006–2010. Aust Fam Physician 2011;40(5):319–22. 21597553

  18. Ortiz M, Simons LA, Calcino G. Generic substitution of commonly used medications: Australia-wide experience, 2007-2008. MedJ Aust. 2010;192(7):370–3. 10.5694/j1326-5377.2010.tb03556.x
  19. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004–2006. Med JAust. 2008;188(4):224–7. 10.5694/j.1326-5377.2008.tb01589.x
  20. Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. MJAust. 2011;195(3):134–7. 10.5694/j.1326-5377.2011.tb03240.x
  21. Simons LA, Ortiz M, Calcino G. Statin-fibrate co-prescription: Australia-wide experience 2007–2010. Australian Journal of Pharmacy. 2011;92(1099):8+10.

  22. Simons LA, Ortiz M, Germanos P, Calcino G. Persistence on warfarin in patients with atrial fibrillation: experience in Australia 2006–2009. Aust Fam Physician. 2013;42(9):659–61. 24024228

  23. Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, et al. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Research Notes. 2015;8:634. 10.1186/s13104-015-1616-8
  24. Paige E, Kemp-Casey A, Korda R, Banks E. Using Australian Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: challenges and approaches. Public Health Res Pract. 2015;25(4):e2541546. 10.17061/phrp2541546
  25. Briffa TG, Jorm L, Jackson RT, Reid C, Chew DP. Nationally linked data to improve health services and policy. Med J Aust. 2019;211(9):397–8.e1. 10.5694/mja2.50368
  26. Schaffer AL, Falster MO, Brieger D, Jorm LR, Wilson A, Hay M, et al. Evidence-Practice Gaps in Postdischarge Initiation With Oral Anticoagulants in Patients With Atrial Fibrillation. J Am Heart Assoc. 2019;8(24):e014287. 10.1161/JAHA.119.014287
  27. Australian Government Department of the Prime Minister and Cabinet. Data Sharing and Release Legislative Reforms Discussion Paper (2019). [cited 05/05/2020]. Available from:

  28. Pharmaceutical Society of Australia. Medicine Safety to be the 10th National Health Priority Area [media release] (2019 November 1). Available from:

  29. Canberra: Federal Department of Health; 2019.
  30. Roughead EE, Kim DS, Ong B, Kemp-Casey A. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price. WHO South-East Asia J of Public Health. 2018;7(2):99–106. 10.4103/2224-3151.239421
  31. Schaffer AL, Buckley NA, Cairns R, Pearson SA. Interrupted time series analysis of the effect of rescheduling alprazolam in Australia: Taking control of prescription drug use. JAMA Intern Med. 2016;176(8):1223–5. 10.1001/jamainternmed.2016.2992
  32. Brett J, Schaffer A, Dobbins T, Buckley NA, Pearson SA. The impact of permissive and restrictive pharmaceutical policies on quetiapine dispensing: Evaluating a policy pendulum using interrupted time series analysis. Pharmacoepidemiology and Drug Safety. 2018;27(4):439–46. 10.1002/pds.4408
  33. Daniels B, Kiely BE, Houssami N, Lord SJ, Dobbins T, Lu CY, et al. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: A national population-based observational study (2006–2014). Br JCancer. 2018;118(3):441–7. 10.1038/bjc.2017.405
  34. Ahmed B, Tran DT, Zoega H, Kennedy SE, Jorm LR, Havard A. Maternal and perinatal outcomes associated with the use of renin-angiotensin system (RAS) blockers for chronic hypertension in early pregnancy. Pregnancy Hypertension. 2018;14:156–61. 10.1016/j.preghy.2018.09.010
  35. Daniels B, Girosi F, Tervonen H, Kiely BE, Lord SJ, Houssami N, et al. Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016). PLoS ONE. 2018;13(7):e0198152. 10.1371/journal.pone.0198152
  36. Lim R, Kerr M, Roughead EE. Use of medicines and health services for chronic obstructive pulmonary disease among a cohort of Australians over 50 years. Int JChron Obstruct Pulmon Dis. 2018;13:3085–93. 10.2147/COPD,S172495,S172495
  37. Simons LA, Chung E. Are high coronary risk patients missing out on lipid-lowering drugs in Australia? Med J Aust. 2014;201(4):213–6. 10.5694/mja14.00249
  38. McLachlan AJ, Aslani P. National Medicines Policy 2.0: a vision for the future. Aust Prescr. 2020;43(1):24–6. 10.18733/austprecr.2020.007
  39. Srinivasan U, Rao S, Ramachandran D, Jonas D. 2016, Flying blind: Australian consumers and digital health, Volume 1: Australian health data series, Health Market Quality Research Program, CMCRC, Sydney. Available from:

  40. Mitchell RJ, Cameron CM, McClure RJ, Williamson AM. Data linkage capabilities in Australia: practical issues identified by a Population Health Research Network ’Proof of Concept project’. Aust N Z J Public Health. 2015;39(4):319–25. 10.1111/1753-6405.12310
  41. Australian Government: Data legislation; 2020.
  42. Katz A, Enns J, Smith M, Burchill C, Turner K, Towns IJPDS. Population Data Centre Profile: The Manitoba Centre for Health Policy. 2019;4(2).

  43. Jones KH, Ford DV, Thompson S, Lyons R IJPDS. A profile of the Sail Databank on the UK secure research platform. 2019;4(2). 10.23889/ijpds.v4i2.1130

Article Details

How to Cite
de Oliveira Costa, J., Bruno, C., L Schaffer, A., Raichand, S. ., A Karanges , E. . and Pearson, S.-A. . (2021) “The changing face of Australian data reforms: Impact on pharmacoepidemiology research”, International Journal of Population Data Science, 6(1). doi: 10.23889/ijpds.v6i1.1418.